Last updated on August 2019

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Brief description of study

This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).

Clinical Study Identifier: NCT03742973

Find a site near you

Start Over

Royal Surrey County Hospital

Guildford, United Kingdom
  Connect »